Shire (SHP)


SHP Share PerformanceMore

52 week high5,377.0 20/09/16
52 week low2,707.0 13/07/16
52 week change 470.5 (11.62%)
4 week volume49,650,913 29/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Declaration

Director Declaration June 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the ?Company?) announces that Flemming Ornskov, MD, MPH, Chief Executive Officer of the Company, was appointed to the Board of Directors of Waters Corporation on June 22, 2017. This notification is to satisfy the Company?s obligations under LR 9.6.14R of the UK Listing Rules. Stephe...

Broker Forecast - Citigroup issues a broker note on Shire PLC

Citigroup today reaffirms its buy investment rating on Shire PLC (LON:SHP) and set its price target at 6500p.

Pound rebounds after Queen's Speech

Sterling bounced back from earlier weakness as the Queen's Speech suggested there may be a softer tone on Brexit. UK Pri...

FTSE and sterling fall ahead of Queen's Speech

The FTSE 100 was trading 0.3% lower as the market looked ahead to the Queen's Speech, which was expected to include new...

FTSE down ahead of Queen's Speech as GBP, oil falter

The FTSE began lower with sterling falling notably against the dollar and euro as the market awaits the Queen's Speech lat...

Shire says US FDA approves Mydayis for ADHD

Shire said the US FDA has approved Mydayis, a once-daily treatment comprised of three different types of drug-releasing ...

Regulatory Approval

U.S. FDA Approves Mydayis TM (mixed salts of a single-entity amphetamine product) ? A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measur...

Broker Forecast - Deutsche Bank issues a broker note on Shire PLC

Deutsche Bank today reaffirms its buy investment rating on Shire PLC (LON:SHP) and cut its price target to 6000p (from...

Latest discussion posts More

  • Re: Good growth prospects IMO

    Rhigos = sentiment is certainly under pressure, with quite a big sell day today, and I really dont know if the Trump is still causing uncertainty (alas he is BAD NEWS!) but ...
    Andy Reilly
  • Re: Shire news

  • Shire news

    Shire has announced positive topline Phase 3 results for the HELP study that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 ...
    Proverbs 26 vs 5

Users' HoldingsMore

Users who hold Shire also hold..

Codes & Symbols